Citations

Showing 10 of 108152 citations.

Haemodynamics of left ventricular apical pouch: is Doppler obstructing us from seeing the full story?
Jain, C. Charles , Newman, Darrell B. , Miranda, William R. , Nishimura, Rick A.

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | June 17, 2021 | Volume: 22 | Issue: 9 | Pages: e138-e138

10.1093/ehjci/jeab121 | PMID 34245251 Get It

Mild to moderate COVID-19 illness in adult outpatients
Blair, Janis E. , Gotimukul, Ashwini, Mina, Syeda A. , Bartels, Helen Caroline , Burns, Mark W. , Kole, Amy E., Vikram, Holenarasipur R. , Gea‐Banacloche, Juan , Seville, Maria Teresa , Petty, Skye A. Buckner, Vikram, Avinash, Orenstein, Robert , Wang, Fangfang, Bartels, Helen C, Vikram, Holenarasipur R. , Wang, Fangfang, Burns, Mark W., Kole, Amy

Mayo Clinic

Medicine | June 17, 2021 | Volume: 100 | Issue: 24 | Pages: e26371

10.1097/md.0000000000026371 | PMID 34128896 Get It

Abstract Most patients with coronavirus disease 2019 (COVID-19) have mild to moderate illness not requiring hospitalization. However, no study has detailed the evolution of symptoms in the first month of illness. At our institution, we conducted remote (telephone and video) visits for all adult outpatients diagnosed with COVID-19 within 24 h of a positive nasopharyngeal polymerase chain test for SARS-CoV-2. We repeated regular video visits at 7, 14, and 28 days after the positive test, retrospectively reviewed the prospective data collected in the remote visits, and constructed a week by week profile of clinical illness, through week 4 of illness. We reviewed the courses of 458 symptomatic patients diagnosed between March 12, 2020, and June 22, 2020, and characterized their weekly courses. Common initial symptoms included fever, headache, cough, and chest pain, which frequently persisted through week 3 or longer. Upper respiratory or gastrointestinal symptoms were much shorter lived, present primarily in week 1. Anosmia/ageusia peaked in weeks 2 to 3. Emergency department visits were frequent, with 128 visits in the 423 patients who were not hospitalized and 48 visits among the 35 outpatients (7.6%) who were eventually hospitalized (2 subsequently died). By the fourth week, 28.9% said their illness had completely resolved. After the 4-week follow up, 20 (4.7%) of the 423 nonhospitalized patients had further medical evaluation and management for subacute or chronic COVID-19 symptoms. Mild to moderate outpatient COVID-19 is a prolonged illness, with evolving symptoms commonly lasting into the fourth week of illness.
VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases
Ekstrom, Thomas L. , Pathoulas, Nicholas M. , Huehls, Amelia M. , Kanakkanthara, Arun , Karnitz, Larry M.

Mayo Clinic

Molecular Cancer Therapeutics | June 17, 2021 | Volume: 20 | Issue: 9 | Pages: 1561-1571

10.1158/1535-7163.mct-20-1099 | PMID 34224364 Get It

Abstract Tumors with defective homologous recombination (HR) DNA repair are more sensitive to chemotherapies that induce lesions repaired by HR as well as PARP inhibitors (PARPis). However, these therapies have limited activity in HR-proficient cells. Accordingly, agents that disrupt HR may be a means to augment the activities of these therapies in HR-proficient tumors. Here we show that VLX600, a small molecule that has been in a phase I clinical trial, disrupts HR and synergizes with PARPis and platinum compounds in ovarian cancer cells. We further found that VLX600 and other iron chelators disrupt HR, in part, by inhibiting iron-dependent histone lysine demethylases (KDM) family members, thus blocking recruitment of HR repair proteins, including RAD51, to double-strand DNA breaks. Collectively, these findings suggest that pharmacologically targeting KDM family members with VLX600 may be a potential novel strategy to therapeutically induce HR defects in ovarian cancers and correspondingly sensitize them to platinum agents and PARPis, two standard-of-care therapies for ovarian cancer.
CPAP adherence is associated with reduced inpatient utilization among older adult Medicare beneficiaries with pre-existing cardiovascular disease
Bailey, M. Doyinsola , Oldstone, Liesl, Johnson, Abree , Scharf, Steven M. , Albrecht, Jennifer S. , Wickwire, Emerson M. , Somers, Virend K. , Srivastava, Mukta Chandra

Mayo Clinic

Journal of Clinical Sleep Medicine | June 17, 2021 | Volume: 18 | Issue: 1 | Pages: 39-45

10.5664/jcsm.9478 | PMID 34170251 Get It

IMPACT OF TIME TO RELAPSE AND RESPONSE TO SALVAGE THERAPY ON POST AUTOLOGOUS STEM CELL TRANSPLANT OUTCOMES IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
Wang, Y, Maliske, Seth , Micallef, Ivana N. , Inwards, David J. , Porrata, Luis F. , Ansell, Stephen M. , Kharfan‐Dabaja, Mohamed A. , Nowakowski, Grzegorz S. , Johnston, Patrick B. , Tun, Aung M. , Farooq, Umar , Rosenthal, Allison , Link, Brian K. , Villasboas, José C. , Paludo, Jonas , Cerhan, James R. , Habermann, Thomas M. , Witzig, Thomas E.

Mayo Clinic

Hematological Oncology | June 17, 2021 | Volume: 39 | Issue: S2 | Pages: No page available

10.1002/hon.98_2880 Get It

INTERIM PET/CT PREDICTS OUTCOMES OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH FRONTLINE LENALIDOMIDE/RCHOP (R2CHOP): LONG‐TERM ANALYSIS OF MC078E
LaPlant, Betsy, Macon, William R. , King, Rebecca L. , Wang, Y., Inwards, David J. , Micallef, Ivana N. , Johnston, Patrick B. , Porrata, Luis F. , Ansell, Steven M., Nowakowski, G. S., Desai, Sanjal H. , Young, J., Habermann, Thomas M. , Witzig, Thomas E.

Mayo Clinic

Hematological Oncology | June 17, 2021 | Volume: 39 | Issue: S2 | Pages: No page available

10.1002/hon.83_2880 Get It

PRIMARY EXTRANODAL FOLLICULAR LYMPHOMA IN A LARGE RETROSPECTIVE SURVEY OF THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG31)
Conconi, Annarita , Vannata, Barbara , Ramírez, Ana Francisca , Bodoni, Chiara Lobetti, Nowakowski, Grzegorz S. , Mian, Michael , Ferreri, Andrés J.M. , Ryan, G.B., Pangalis, G., Cabrera, María Elena , Aurer, Igor , Visco, Carlo , Mazzucchelli, Luca, Federico, Massimo, López‐Guillermo, Armando , Pro, Barbara, Janikova, Andrea , Ramirez, A., Luminari, Stefano , Montoto, Silvia , Tsang, Richard , Trněný, Marek , Gaïdano, Gianluca , Zucca, Emanuele

Mayo Clinic

Hematological Oncology | June 17, 2021 | Volume: 39 | Issue: S2 | Pages: No page available

10.1002/hon.78_2879 Get It

NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY
Ansell, Stephen M. , Bröckelmann, Paul J. , Keudell, Gottfried von , Lee, H. J., Cohen, Jonathon B. , Jaeger, Ulrich, Willenbacher, Wolfgang , Swanink, René, Engert, Andreas , Armand, Philippe , Santoro, Armando , Zinzani, Pier Luigi , Collins, Graham P. , Boer, Jan Paul de , Kuruvilla, John , Savage, Kerry J. , Trněný, Marek , Sacchi, M., Shipp, Margaret Ann

Mayo Clinic

Hematological Oncology | June 17, 2021 | Volume: 39 | Issue: S2 | Pages: No page available

10.1002/hon.74_2879 Get It

TRIPLE POSITIVE (CD10+BCL6+MUM1+) DIFFUSE LARGE B‐CELL LYMPHOMAS IN ADULTS ARE A HETEROGENEOUS GROUP ENRICHED IN LARGE B‐CELL LYMPHOMAS WITH IRF4 REARRANGEMENT
Frauenfeld, Leonie , Castrejon‐de‐Anta, N., Ramis‐Zaldivar, Juan Enric, Otto, Franziska, Streich, S. , Salmerón‐Villalobos, Julia , Mayer, A., Steinhilber, Julia , Pinyol, M., Mankel, Barbara, Bonzheim, Irina , Rimza, L., Castrejon‐de‐Anta, N., Mayer, A., Fend, Falko , Salaverría, Itziar , Campo, Elı́as , Balagué, Olga , Quintanilla‐Martínez, Leticia

Mayo Clinic

Hematological Oncology | June 17, 2021 | Volume: 39 | Issue: S2 | Pages: No page available

10.1002/hon.69_2879 Get It